Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials-Reference-Cited by-同舟云学术

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials

Published:2015-06-15 Issue:6 Volume:4 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

Li Chuanwei¹,Lin Ling²,Zhang Wen³,Zhou Liang⁴,Wang Hongyong¹,Luo Xiaoli¹,Luo Hao¹,Cai Yue¹,Zeng Chunyu¹

Affiliation:

1. Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China

2. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China

3. Department of Respirology, Xinqiao Hospital, Third Military Medical University, Chongqing, China

4. Department of Health Statistics, College of Preventive Medicine, Third Military Medical University, Chongqing, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference53 articles.

1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

3. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report

4. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy

5. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Predictive Utility of Circulating PCSK9 Levels on Diabetic Retinopathy Stage;Current Eye Research;2024-07-31

2. Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis;Current Medicinal Chemistry;2024-01

3. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials;European Heart Journal - Cardiovascular Pharmacotherapy;2023-03-27

4. Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study;Journal of Inflammation Research;2023-01

5. Acute impact of the early application of alirocumab on lipoprotein (a) and interleukin-6 in patients with unstable angina pectoris: a retrospective before-after study;2022-09-21